Therapeutic efficacy of a novel Nanosomal Docetaxel lipid suspension compared with Taxotere in locally advanced or Metastatic breast cancer patients

Ateeq Ahmad, Saifuddin Sheikh, Rakesh Taran, Shanti P. Srivastav, Krishna Prasad, Senthil J. Rajappa, Vijay Kumar, Mamillapalli Gopichand, Mahesh Paithankar, Manish Sharma, Rajendra C. Rane, Imran Ahmad

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Background Nanosomal docetaxel lipid suspension formulation was developed to eliminate ethanol and polysorbate 80 from the currently used docetaxel (Taxotere) drug for treatment of cancer patients. NDLS clinical safety and efficacy was evaluated and compared with Taxotere at 75 mg/m2 in metastatic breast cancer patients. Patients and Methods A total of 72 patients were randomized in a ratio of 2:1 (NDLS:Taxotere). Patients treated with NDLS were not premedicated with corticosteroids as required with solvent-based Taxotere. Disease status and tumor response was assessed after every 2 cycles of treatment using Response Evaluation Criteria in Solid Tumors 1.1 guidelines through cycle 6. Results Overall therapeutic response (complete + partial) rate in metastatic breast cancer patients treated with NDLS and Taxotere were 35.5% and 26.3%, respectively, indicating better response in patients treated with NDLS. Patients in the NDLS group were not premedicated but the safety results of NDLS were found to be comparable with Taxotere. Conclusion NDLS formulation with no premedication provides an alternative treatment option for breast cancer patients.

Original languageEnglish
Pages (from-to)177-181
Number of pages5
JournalClinical Breast Cancer
Volume14
Issue number3
DOIs
Publication statusPublished - 01-01-2014
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Therapeutic efficacy of a novel Nanosomal Docetaxel lipid suspension compared with Taxotere in locally advanced or Metastatic breast cancer patients'. Together they form a unique fingerprint.

Cite this